$1,318.00
This Market Spotlight report covers the Gout market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Gout market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, key regulatory events, recent events and analyst opinion, a 10-year disease prevalence forecast, and probability of success, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Non-steroidal anti-inflammatory drugs (NSAIDs)
9 Corticosteroids
9 Colchicine
9 Combination therapy
10 Prevention of chronic gout
11 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 DYV-702 for Gout (June 1, 2022)
24 ALLN-346 for Gout (January 4, 2022)
26 LC350189 for Gout (July 1, 2021)
28 KEY UPCOMING EVENTS
29 KEY REGULATORY EVENTS
29 Sawai Focuses On New Products, Supply To ‘Retain Trust’ of Japan Generic Industry
30 PROBABILITY OF SUCCESS
31 REVENUE OPPORTUNITY
33 CLINICAL TRIAL LANDSCAPE
34 Sponsors by status
35 Sponsors by phase
36 Recent events
38 BIBLIOGRAPHY
39 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of gout, 2021–30
18 Figure 2: Overview of pipeline drugs for gout in the US
18 Figure 3: Pipeline drugs for gout, by company
19 Figure 4: Pipeline drugs for gout, by drug type
19 Figure 5: Pipeline drugs for gout, by classification
24 Figure 6: DYV-702 for Gout (June 1, 2022): Phase IIa – TARGETS
26 Figure 7: ALLN-346 for Gout (January 4, 2022): Phase IIa – 201
27 Figure 8: LC350189 for Gout (July 1, 2021): Phase II – CLUE
28 Figure 9: Key upcoming events in gout
30 Figure 10: Probability of success in the arthritis pipeline
33 Figure 11: Clinical trials in gout
33 Figure 12: Top 10 drugs for clinical trials in gout
34 Figure 13: Top 10 companies for clinical trials in gout
34 Figure 14: Trial locations in gout
35 Figure 15: Gout trials status
36 Figure 16: Gout trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of gout, 2021–30
16 Table 2: Marketed drugs for gout
20 Table 3: Pipeline drugs for gout in the US
23 Table 4: DYV-702 for Gout (June 1, 2022)
25 Table 5: ALLN-346 for Gout (January 4, 2022)
26 Table 6: LC350189 for Gout (July 1, 2021)
31 Table 7: Historical global sales, by drug ($m), 2017–21
32 Table 8: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!